Indication
Gammopathy
3 clinical trials
5 products
Clinical trial
A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible (EAE 120)Status: Recruiting, Estimated PCD: 2026-03-15
Product
Belantamab MafodotinProduct
DaratumumabProduct
LenalidomideProduct
DexamethasoneClinical trial
A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administrated in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple MyelomaStatus: Recruiting, Estimated PCD: 2026-10-31
Clinical trial
Pilot Study of Oral Rifaximin in Patients With Monoclonal GammopathyStatus: Recruiting, Estimated PCD: 2025-11-30
Product
Rifaximin